Overview

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Status:
Recruiting
Trial end date:
2022-02-03
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Incyte Corporation